冬季新品三部曲之“IO腫瘤免疫細胞株”

I wish you a merry Christmas. All affection and best wishes to you and yours.

Silent night！Holy night！

All is calm, all is bright！

Christmas Eve is the red heart in the snow armor,

 Cobioer will bring you IO tumor immune cell line.

新品簡介

免疫檢查點分子逐漸被認為是腫瘤免疫治療的新靶標，它通常被腫瘤細胞“劫持”，以束縛免疫系統發揮有效的抗腫瘤反應的能力。免疫檢查點阻斷（Immune Checkpoint Blockade）是激活抗腫瘤免疫的有希望的方法。細胞毒性T淋巴細胞相關抗原4（CTLA-4）和程序性細胞死亡受體1（PD-1）是目前研究的透徹的免疫檢查點分子，anti-CTLA4和anti-PD1單克隆藥物已經在多種惡性腫瘤的臨床試驗中展現出不錯的療效。

案例展示

OX40 / CD134是腫瘤壞死因子（TNF）受體家族的成員。它是一種有效的共刺激途徑的一部分，當被觸發時可以在幾種臨床前癌癥模型以及人類中增強T細胞記憶，增殖和抗腫瘤活性，從而克服癌癥的一些免疫抑制性質。

OX40 / CD134 is a member of the tumor necrosis factor (TNF) receptor family. It is part of a potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation and antitumor activity in several preclinical cancer models as well as in humans thus overcoming some of the immunosuppressive properties of cancer. 

Fig 1. FACS analysis of OX40 in HEK293 cells

OX40-HEK293 cells were stained with FITC-labeled anti-OX40 antibody and analyzed by FACS.

Y-axis shows the cell count. X-axis shows the intensity of FITC fluorescence.  

Fig 2. Dose Response of OX40 / NF-κB Reporter – HEK293 cells to OX40L. The results are shown as RLU signal of NF-κB luciferase reporter expression. The EC50 of OX40L is 6.5 ng/ml.

Fig 3. OX40/OX40L Immune Checkpoint Pathway

熱門產品